| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Endocrine Care |
Developmental Endocrinology Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892
Address all correspondence and requests for reprints to: Dr. Karen Klein, Pediatric Endocrinologist, 6633 Maycrest Lane, San Diego, California 92121. E-mail: koklein{at}juno.com
Abstract
We report 98 children who have reached final adult height in a long-term trial of LHRH agonist treatment. These children were 5.3 ± 2.1 yr old at the start of treatment and were treated with either deslorelin (4 µg/kg·d sc) or histrelin (4–10 µg/kg·d) for an average of 6.1 ± 2.5 yr. Final height averaged 159.8 ± 7.6 cm in the 80 girls, which was significantly greater than pretreatment predicted height (149.3 ± 9.6 cm) but still significantly less than midparental height (MPH) (163.7 ± 5.6). Final height averaged 171.1 ± 8.7 cm in the 18 boys, which was significantly greater than pretreatment predicted height (156.1 ± 14.2 cm) but still significantly less than MPH (178.3 ± 5.2 cm). However, the average adult height of the 54 children who had less than a 2-yr delay in the onset of treatment was not significantly different from their MPH, and 21 children exceeded MPH.
Final height SD score correlated positively with duration of treatment (P < 0.01), midparental height (P < 0.001), predicted height at the start of treatment (P < 0.001), and growth velocity during the last year of treatment (P < 0.001) and correlated inversely with delay in the onset of treatment (P < 0.001), age at the start of treatment (P < 0.001), bone age at the start of treatment (P < 0.001), bone age at the end of treatment (P < 0.001), breast stage at the start of treatment (P = 0.02), and bone age minus chronological age at the start of treatment (P = 0.001).
We conclude that LHRH agonist treatment improves the final height for children with rapidly progressing precocious puberty treated before the age of 8 yr for girls or 9 yr for boys. Less delay in the onset of treatment, longer duration of treatment, and lower chronological and bone age at the onset of treatment all lead to greater final height. All children with onset of pubertal symptoms before age 8 in girls and age 9 in boys should be evaluated for possible treatment. Treatment is appropriate in children with rapidly progressing puberty, accelerated bone maturation, and compromise of adult height prediction, regardless of bone age or chronological age at time of evaluation. However, once treatment is considered appropriate, it should be initiated quickly, because longer delays lead to shorter final height. In addition, the longer the treatment is continued, the greater is the final height outcome.
This article has been cited by other articles:
 |
|
 |
|
  J.-C. Carel, E. A. Eugster, A. Rogol, L. Ghizzoni, M. R. Palmert, and on behalf of the members of the ESPE-LWPES GnRH An Consensus Statement on the Use of Gonadotropin-Releasing Hormone Analogs in Children Pediatrics, April 1, 2009; 123(4): e752 - e762. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. N. Brito, A. C. Latronico, P. Cukier, M. G. Teles, L. F. G. Silveira, I. J. P. Arnhold, and B. B. Mendonca Factors Determining Normal Adult Height in Girls with Gonadotropin-Dependent Precocious Puberty Treated with Depot Gonadotropin-Releasing Hormone Analogs J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2662 - 2669. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-C. Carel and J. Leger Precocious Puberty N. Engl. J. Med., May 29, 2008; 358(22): 2366 - 2377. [Full Text] [PDF]
|
|
|
|
|
|
A. M. Pasquino, I. Pucarelli, F. Accardo, V. Demiraj, M. Segni, and R. Di Nardo Long-Term Observation of 87 Girls with Idiopathic Central Precocious Puberty Treated with Gonadotropin-Releasing Hormone Analogs: Impact on Adult Height, Body Mass Index, Bone Mineral Content, and Reproductive Function J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 190 - 195. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Lazar, A. Padoa, and M. Phillip Growth Pattern and Final Height after Cessation of Gonadotropin-Suppressive Therapy in Girls with Central Sexual Precocity J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3483 - 3489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Eugster, W. Clarke, G. B. Kletter, P. A. Lee, E. K. Neely, E. O. Reiter, P. Saenger, D. Shulman, L. Silverman, L. Flood, et al. Efficacy and Safety of Histrelin Subdermal Implant in Children with Central Precocious Puberty: A Multicenter Trial J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1697 - 1704. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ben-Haroush, H. Goldberg-Stern, M. Phillip, and L. de Vries GnRH agonist treatment in girls with precocious puberty does not compromise post-pubertal uterine size Hum. Reprod., March 1, 2007; 22(3): 895 - 900. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Muir Precocious Puberty Pediatr. Rev., October 1, 2006; 27(10): 373 - 381. [Full Text] [PDF]
|
|
|
|
|
|
T. Tanaka, H. Niimi, N. Matsuo, K. Fujieda, K. Tachibana, K. Ohyama, M. Satoh, and K. Kugu Results of Long-Term Follow-Up after Treatment of Central Precocious Puberty with Leuprorelin Acetate: Evaluation of Effectiveness of Treatment and Recovery of Gonadal Function. The TAP-144-SR Japanese Study Group on Central Precocious Puberty J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1371 - 1376. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Brownstein, A. C. Mertens, P. A. Mitby, M. Stovall, J. Qin, G. Heller, L. L. Robison, and C. A. Sklar Factors That Affect Final Height and Change in Height Standard Deviation Scores in Survivors of Childhood Cancer Treated with Growth Hormone: A Report from the Childhood Cancer Survivor Study J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4422 - 4427. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-C. Carel, N. Lahlou, M. Roger, and J. L. Chaussain Precocious puberty and statural growth Hum. Reprod. Update, March 1, 2004; 10(2): 135 - 147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Weise, A. Flor, K. M. Barnes, G. B. Cutler Jr., and J. Baron Determinants of Growth during Gonadotropin-Releasing Hormone Analog Therapy for Precocious Puberty J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 103 - 107. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.-S. Parent, G. Teilmann, A. Juul, N. E. Skakkebaek, J. Toppari, and J.-P. Bourguignon The Timing of Normal Puberty and the Age Limits of Sexual Precocity: Variations around the World, Secular Trends, and Changes after Migration Endocr. Rev., October 1, 2003; 24(5): 668 - 693. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Yanovski, S. R. Rose, G. Municchi, O. H. Pescovitz, S. C. Hill, F. G. Cassorla, and G. B. Cutler Jr. Treatment with a Luteinizing Hormone-Releasing Hormone Agonist in Adolescents with Short Stature N. Engl. J. Med., March 6, 2003; 348(10): 908 - 917. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Antoniazzi, G. Zamboni, F. Bertoldo, S. Lauriola, F. Mengarda, A. Pietrobelli, and L. Tato Bone Mass at Final Height in Precocious Puberty after Gonadotropin-Releasing Hormone Agonist with and without Calcium Supplementation J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1096 - 1101. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Morgan, D. Conklin, A. J. Pawson, R. Sellar, T. R. Ott, and R. P. Millar A Transcriptionally Active Human Type II Gonadotropin-Releasing Hormone Receptor Gene Homolog Overlaps Two Genes in the Antisense Orientation on Chromosome 1q.12 Endocrinology, February 1, 2003; 144(2): 423 - 436. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-C. Carel, N. Lahlou, O. Jaramillo, V. Montauban, C. Teinturier, M. Colle, C. Lucas, and J. L. Chaussain Treatment of Central Precocious Puberty by Subcutaneous Injections of Leuprorelin 3-Month Depot (11.25 mg) J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4111 - 4116. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
